TY - JOUR
T1 - Liver X receptors agonist promotes differentiation of rat bone marrow derived mesenchymal stem cells into dopaminergic neuron-like cells
AU - Cheng, Oumei
AU - Tian, Xiaoyan
AU - Luo, Ying
AU - Mai, Shaoshan
AU - Yang, Yang
AU - Kuang, Shengnan
AU - Chen, Qi
AU - Ma, Jie
AU - Chen, Beibei
AU - Li, Rong
AU - Yang, Lu
AU - Li, Huan
AU - Hu, Congli
AU - Zhang, Jiahua
AU - Chen, Zhihao
AU - Li, Yuke
AU - Xia, Hui
AU - Xu, Ying
AU - Yang, Junqing
N1 - Publisher Copyright:
© Cheng et al.
PY - 2018
Y1 - 2018
N2 - Dopaminergic (DA) neurons derived from bone marrow derived mesenchymal stem cells (BMSCs) maybe a valuable source for cell replacement therapy in Parkinson disease. Recent studies showed that new functions of LXR and their ligands have been proposed to prevent PD in the adult nervous system. The present study was designed to observe the effect of liver X receptors (LXR) agonist on differentiation of rat BMSCs into DA neurons. Expressions of the neuronal markers (Tuj1 and Nestin), the specific marker of DA neurons (tyrosine hydroxylase, TH), LXR α and LXR β were measured by immunocytochemical assay and TH/Tuj1 positive cells were determined by quantitative cell count analyses. mRNA expressions of LXR α, LXR β, TH, DAT, Nurr1, Pitx3, En1 and Lmx1b were measured by qPCR. Compared with growth factors (GF) treated group, combined use of LXR and GF induced rat BMSCs to TH-expressing cells with 87.42% of efficiency in 6 days of period of induction. LXR agonist alone did not induce the differentiation. Compared with GF alone, combined use of LXR and GF increased expressions of LXR α and LXR β protein and mRNA and TH, DAT, Nurr1, and Pitx3 mRNA, decreased expressions of En1 and Lmx1b mRNA. Our experimental results indicated that LXR activation leads to improve induction efficiency and shorten induction period of rat BMSCs into DA neuron-like cells through regulating DA development-related genes expressions and that LXR can be considered as a candidate target for drug development to improve differentiation of BMSCs into DA neurons.
AB - Dopaminergic (DA) neurons derived from bone marrow derived mesenchymal stem cells (BMSCs) maybe a valuable source for cell replacement therapy in Parkinson disease. Recent studies showed that new functions of LXR and their ligands have been proposed to prevent PD in the adult nervous system. The present study was designed to observe the effect of liver X receptors (LXR) agonist on differentiation of rat BMSCs into DA neurons. Expressions of the neuronal markers (Tuj1 and Nestin), the specific marker of DA neurons (tyrosine hydroxylase, TH), LXR α and LXR β were measured by immunocytochemical assay and TH/Tuj1 positive cells were determined by quantitative cell count analyses. mRNA expressions of LXR α, LXR β, TH, DAT, Nurr1, Pitx3, En1 and Lmx1b were measured by qPCR. Compared with growth factors (GF) treated group, combined use of LXR and GF induced rat BMSCs to TH-expressing cells with 87.42% of efficiency in 6 days of period of induction. LXR agonist alone did not induce the differentiation. Compared with GF alone, combined use of LXR and GF increased expressions of LXR α and LXR β protein and mRNA and TH, DAT, Nurr1, and Pitx3 mRNA, decreased expressions of En1 and Lmx1b mRNA. Our experimental results indicated that LXR activation leads to improve induction efficiency and shorten induction period of rat BMSCs into DA neuron-like cells through regulating DA development-related genes expressions and that LXR can be considered as a candidate target for drug development to improve differentiation of BMSCs into DA neurons.
KW - Bone marrow derived mesenchymal stem cells and cell differentiation
KW - Dopaminergic neurons
KW - Liver X receptors
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85040628172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040628172&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.23076
DO - 10.18632/oncotarget.23076
M3 - Article
C2 - 29416637
AN - SCOPUS:85040628172
SN - 1949-2553
VL - 9
SP - 576
EP - 590
JO - Oncotarget
JF - Oncotarget
IS - 1
ER -